[go: up one dir, main page]

CL2008001384A1 - Preparacion farmaceutica acuosa de 1-(2-dimetilamino-etil)-3-((2r, 4as, 5r, 10bs)-5-fenil-9-trifluorometil-3,4,4a,5,6,10b-hexahidro-2h-pirano (3,2-c)quinolin-2-ilmetil)-urea, un tensoactivo no ionico y al menos un solvente organico con grupos hidroxilos; preparacion farmaceutica liquida; procedimiento para producirla; kit farmaceutico. - Google Patents

Preparacion farmaceutica acuosa de 1-(2-dimetilamino-etil)-3-((2r, 4as, 5r, 10bs)-5-fenil-9-trifluorometil-3,4,4a,5,6,10b-hexahidro-2h-pirano (3,2-c)quinolin-2-ilmetil)-urea, un tensoactivo no ionico y al menos un solvente organico con grupos hidroxilos; preparacion farmaceutica liquida; procedimiento para producirla; kit farmaceutico.

Info

Publication number
CL2008001384A1
CL2008001384A1 CL2008001384A CL2008001384A CL2008001384A1 CL 2008001384 A1 CL2008001384 A1 CL 2008001384A1 CL 2008001384 A CL2008001384 A CL 2008001384A CL 2008001384 A CL2008001384 A CL 2008001384A CL 2008001384 A1 CL2008001384 A1 CL 2008001384A1
Authority
CL
Chile
Prior art keywords
pharmaceutical preparation
quinolin
hexahydro
ylmethyl
dimethylamino
Prior art date
Application number
CL2008001384A
Other languages
English (en)
Inventor
Holger Bauer
Norbert Rasenack
Kerstin Ammer
Bianka Kemmerer
Kirstin Heil
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CL2008001384A1 publication Critical patent/CL2008001384A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Preparación farmacéutica acuosa que contiene 1-(2-dimetilamino-etil)-3-((2r, 4as, 5r, 10bs)-5-fenil-9-trifluorometil-3,4,4a,5,6,10b-hexahidro-2h-pirano[3,2-c]quinolin-2-ilmetil)-urea, al menos un tensioactivo no iónico y al menos un solvente orgánico que contiene por lo menos un hidroxilo; y kit que la comprende.
CL2008001384A 2007-05-10 2008-05-09 Preparacion farmaceutica acuosa de 1-(2-dimetilamino-etil)-3-((2r, 4as, 5r, 10bs)-5-fenil-9-trifluorometil-3,4,4a,5,6,10b-hexahidro-2h-pirano (3,2-c)quinolin-2-ilmetil)-urea, un tensoactivo no ionico y al menos un solvente organico con grupos hidroxilos; preparacion farmaceutica liquida; procedimiento para producirla; kit farmaceutico. CL2008001384A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007021862A DE102007021862A1 (de) 2007-05-10 2007-05-10 Wässrige pharmazeutische Zubereitung

Publications (1)

Publication Number Publication Date
CL2008001384A1 true CL2008001384A1 (es) 2009-09-25

Family

ID=39537491

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001384A CL2008001384A1 (es) 2007-05-10 2008-05-09 Preparacion farmaceutica acuosa de 1-(2-dimetilamino-etil)-3-((2r, 4as, 5r, 10bs)-5-fenil-9-trifluorometil-3,4,4a,5,6,10b-hexahidro-2h-pirano (3,2-c)quinolin-2-ilmetil)-urea, un tensoactivo no ionico y al menos un solvente organico con grupos hidroxilos; preparacion farmaceutica liquida; procedimiento para producirla; kit farmaceutico.

Country Status (20)

Country Link
US (1) US20100210681A1 (es)
EP (1) EP2142169B1 (es)
JP (1) JP2010526783A (es)
KR (1) KR20100029758A (es)
CN (1) CN101677941A (es)
AR (1) AR066504A1 (es)
AT (1) ATE530164T1 (es)
AU (1) AU2008250717A1 (es)
BR (1) BRPI0811431A2 (es)
CA (1) CA2686765A1 (es)
CL (1) CL2008001384A1 (es)
CO (1) CO6220901A2 (es)
DE (1) DE102007021862A1 (es)
EA (1) EA200901498A1 (es)
EC (1) ECSP099788A (es)
IL (1) IL201912A0 (es)
MX (1) MX2009012035A (es)
PE (1) PE20090246A1 (es)
TW (1) TW200911252A (es)
WO (1) WO2008138459A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2948568B1 (fr) * 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique
US20130029919A1 (en) * 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
KR102126727B1 (ko) 2018-03-29 2020-07-07 이혜영 자동차 표면 광택방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2033959E (pt) * 2003-12-20 2011-07-29 Merck Patent Gmbh Derivados de tetra-hidropiranoquinolina
US7361683B2 (en) * 2004-11-24 2008-04-22 Yung Shin Pharm. Ind., Co., Ltd Paclitaxel aqueous injection solution and methods for preparing the same
EA015994B1 (ru) * 2006-06-19 2012-01-30 Мерк Патент Гмбх Способ получения энантиомерно обогащенных или чистых соединений

Also Published As

Publication number Publication date
KR20100029758A (ko) 2010-03-17
JP2010526783A (ja) 2010-08-05
AU2008250717A1 (en) 2008-11-20
BRPI0811431A2 (pt) 2015-06-16
CA2686765A1 (en) 2008-11-20
ATE530164T1 (de) 2011-11-15
IL201912A0 (en) 2010-06-16
CN101677941A (zh) 2010-03-24
WO2008138459A3 (de) 2009-06-04
AR066504A1 (es) 2009-08-26
PE20090246A1 (es) 2009-03-19
EP2142169A2 (de) 2010-01-13
US20100210681A1 (en) 2010-08-19
ECSP099788A (es) 2010-01-29
DE102007021862A1 (de) 2008-11-13
EA200901498A1 (ru) 2010-04-30
EP2142169B1 (de) 2011-10-26
TW200911252A (en) 2009-03-16
MX2009012035A (es) 2009-11-18
CO6220901A2 (es) 2010-11-19
WO2008138459A2 (de) 2008-11-20

Similar Documents

Publication Publication Date Title
MX2019006767A (es) Solucion de conservacion de acido nucleico y metodos de elaboracion y uso.
DOP2010000114A (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea
UY31806A (es) Compuestos de tiazole y oxazole de sulfonamida de benceno
CL2008001951A1 (es) Compuestos derivados de imidazo[1,2-a]pirimidin-2-ilmetil sustituidos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el trastorno del sueno, depresion, ansiedad, trastorno relacionado con el abuso de sustancias, entre otras.
HN2010001059A (es) Nuevo titulo modificado: compuestos derivados de pirimidina, un proceso para la preparacion de los mismos, una composicion farmaceutica que los comprenden y combinaciones de dichos compuestos con otros agentes.
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo
CL2008001896A1 (es) 3-dihalometil-1-metil-1h-pirazol-4-carbaldehidos; su proceso de preparacion usando un intermediario de hidrazona, que reacciona con un agente de vilsmeier; y el derivado de hidrazona usado.
AR019262A1 (es) Proceso para la preparacion de una formulacion que comprende una sustancia activa o sustancias activas asociadas con un portador, y formulacion preparadapor dicho proceso.
CR10937A (es) Inhibidores de cinasa mapk/erk
CL2012001310A1 (es) Composicion que comprende un oligopeptido ciclo-(arg-gly-asp-dphe-nmeval) que tiene una solubilidad en agua a 20ºc de entre 1 mg/ml y 20 mg/ml y con uno o varios compuestos lipofilicos y/o anfifílicos; proceso para preparar dicha composicion.
AR059357A1 (es) Formulaciones farmaceuticas
CL2013003307A1 (es) Agente que comprende ciazofamida o fenamidona; y su uso para tratar micosis en peces e invertebrados en todos sus estadios de desarrollo causada por hongos de los generos saprolegnia, achlya y aphanomyces (div.sol.n°1056-08).
PA8577201A1 (es) 3-fenil-propionamido, 3-fenil-acrilamido y derivados 3-fenil-propinamido como inhibidores de mao-b
UY30451A1 (es) 18-metil-19-nor-androst-4-en-17,17-espiroéteres (18-metil-19-nor-20-espirox-4-en-3-onas),ase como preparaciones farmacéuticas que lo contienen.
CR9411A (es) Agentes secuestrantes para micronutrientes fertilizantes
AR057305A1 (es) Proceso para la preparacion de derivados de sulfamida
CL2011002160A1 (es) Compuestos derivados de 3-amino-2-mercaptoquinolinas sustituidas; composicion farmaceutica que contiene dichos compuestos; y su uso para tratar dolor, epilepsis, incontinencia urinaria, manias, migraña, trastornos bipolares, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria.
HN2006009000A (es) Formas farmaceuticas con propiedades farmacocineticas mejoradas
BRPI0418474A (pt) solução aquosa parenteral estável
GT200900287A (es) Extrudidos con enmascaramiento del sabor mejorado
CL2008001384A1 (es) Preparacion farmaceutica acuosa de 1-(2-dimetilamino-etil)-3-((2r, 4as, 5r, 10bs)-5-fenil-9-trifluorometil-3,4,4a,5,6,10b-hexahidro-2h-pirano (3,2-c)quinolin-2-ilmetil)-urea, un tensoactivo no ionico y al menos un solvente organico con grupos hidroxilos; preparacion farmaceutica liquida; procedimiento para producirla; kit farmaceutico.
GT201000102A (es) Producto de dispersión sólida de drogas basadas en n-aril urea
AR051765A1 (es) Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas
AR070905A1 (es) Procedimiento para la produccion de hidroperoxidos de alquilbenceno bajo condiciones suaves y en presencia de sistemas cataliticos
AR072426A1 (es) Uso de nifurtimox para el tratamiento de enfermedades causadas por tricomonadida